160 related articles for article (PubMed ID: 24533987)
1. 166Ho and 90Y labeled 6D2 monoclonal antibody for targeted radiotherapy of melanoma: comparison with 188Re radiolabel.
Thompson S; Ballard B; Jiang Z; Revskaya E; Sisay N; Miller WH; Cutler CS; Dadachova E; Francesconi LC
Nucl Med Biol; 2014 Mar; 41(3):276-81. PubMed ID: 24533987
[TBL] [Abstract][Full Text] [Related]
2. Pre-clinical evaluation and efficacy studies of a melanin-binding IgM antibody labeled with 188Re against experimental human metastatic melanoma in nude mice.
Dadachova E; Revskaya E; Sesay MA; Damania H; Boucher R; Sellers RS; Howell RC; Burns L; Thornton GB; Natarajan A; Mirick GR; DeNardo SJ; DeNardo GL; Casadevall A
Cancer Biol Ther; 2008 Jul; 7(7):1116-27. PubMed ID: 18535406
[TBL] [Abstract][Full Text] [Related]
3. Radioimmunotherapy of experimental human metastatic melanoma with melanin-binding antibodies and in combination with dacarbazine.
Revskaya E; Jongco AM; Sellers RS; Howell RC; Koba W; Guimaraes AJ; Nosanchuk JD; Casadevall A; Dadachova E
Clin Cancer Res; 2009 Apr; 15(7):2373-9. PubMed ID: 19293257
[TBL] [Abstract][Full Text] [Related]
4. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
5. Computational model predicts effective delivery of 188-Re-labeled melanin-binding antibody to metastatic melanoma tumors with wide range of melanin concentrations.
Schweitzer AD; Rakesh V; Revskaya E; Datta A; Casadevall A; Dadachova E
Melanoma Res; 2007 Oct; 17(5):291-303. PubMed ID: 17885584
[TBL] [Abstract][Full Text] [Related]
6. Complement-dependent cytotoxicity of an antibody to melanin in radioimmunotherapy of metastatic melanoma.
Jandl T; Revskaya E; Jiang Z; Bryan RA; Casadevall A; Dadachova E
Immunotherapy; 2013 Apr; 5(4):357-64. PubMed ID: 23557419
[TBL] [Abstract][Full Text] [Related]
7. Melanoma stem cells in experimental melanoma are killed by radioimmunotherapy.
Jandl T; Revskaya E; Jiang Z; Harris M; Dorokhova O; Tsukrov D; Casadevall A; Dadachova E
Nucl Med Biol; 2013 Feb; 40(2):177-81. PubMed ID: 23146306
[TBL] [Abstract][Full Text] [Related]
8. Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a mAb to melanin.
Dadachova E; Nosanchuk JD; Shi L; Schweitzer AD; Frenkel A; Nosanchuk JS; Casadevall A
Proc Natl Acad Sci U S A; 2004 Oct; 101(41):14865-70. PubMed ID: 15469923
[TBL] [Abstract][Full Text] [Related]
9. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
[TBL] [Abstract][Full Text] [Related]
10. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
[TBL] [Abstract][Full Text] [Related]
11. Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma.
Postema EJ; Frielink C; Oyen WJ; Raemaekers JM; Goldenberg DM; Corstens FH; Boerman OC
Cancer Biother Radiopharm; 2003 Aug; 18(4):525-33. PubMed ID: 14503946
[TBL] [Abstract][Full Text] [Related]
12. Fractionated radioimmunotherapy with ⁹⁰Y-labeled fully human anti-CEA antibody.
Hanaoka H; Kuroki M; Yamaguchi A; Achmad A; Iida Y; Higuchi T; Oriuchi N; Tsushima Y; Endo K
Cancer Biother Radiopharm; 2014 Mar; 29(2):70-6. PubMed ID: 24299067
[TBL] [Abstract][Full Text] [Related]
13. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo evaluation of melanin-binding decapeptide 4B4 radiolabeled with 177Lu, 166Ho, and 153Sm radiolanthanides for the purpose of targeted radionuclide therapy of melanoma.
Ballard B; Jiang Z; Soll CE; Revskaya E; Cutler CS; Dadachova E; Francesconi LC
Cancer Biother Radiopharm; 2011 Oct; 26(5):547-56. PubMed ID: 21970319
[TBL] [Abstract][Full Text] [Related]
15. Toward developing a universal treatment for fungal disease using radioimmunotherapy targeting common fungal antigens.
Bryan RA; Guimaraes AJ; Hopcraft S; Jiang Z; Bonilla K; Morgenstern A; Bruchertseifer F; Del Poeta M; Torosantucci A; Cassone A; Nosanchuk JD; Casadevall A; Dadachova E
Mycopathologia; 2012 Jun; 173(5-6):463-71. PubMed ID: 22048869
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic efficacy of c-kit-targeted radioimmunotherapy using 90Y-labeled anti-c-kit antibodies in a mouse model of small cell lung cancer.
Yoshida C; Tsuji AB; Sudo H; Sugyo A; Kikuchi T; Koizumi M; Arano Y; Saga T
PLoS One; 2013; 8(3):e59248. PubMed ID: 23516616
[TBL] [Abstract][Full Text] [Related]
17. Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model.
Kelly MP; Lee FT; Smyth FE; Brechbiel MW; Scott AM
J Nucl Med; 2006 Apr; 47(4):716-25. PubMed ID: 16595507
[TBL] [Abstract][Full Text] [Related]
18. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles.
Li L; Wartchow CA; Danthi SN; Shen Z; Dechene N; Pease J; Choi HS; Doede T; Chu P; Ning S; Lee DY; Bednarski MD; Knox SJ
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1215-27. PubMed ID: 15001266
[TBL] [Abstract][Full Text] [Related]
19. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies.
Ma D; McDevitt MR; Barendswaard E; Lai L; Curcio MJ; Pellegrini V; Brechbiel MW; Scheinberg DA
Leukemia; 2002 Jan; 16(1):60-6. PubMed ID: 11840264
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of [
Tsai WK; Zettlitz KA; Dahlbom M; Reiter RE; Wu AM
Mol Imaging Biol; 2020 Oct; 22(5):1380-1391. PubMed ID: 32661830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
